SG11201809751XA - Egfr inhibitor compounds - Google Patents

Egfr inhibitor compounds

Info

Publication number
SG11201809751XA
SG11201809751XA SG11201809751XA SG11201809751XA SG11201809751XA SG 11201809751X A SG11201809751X A SG 11201809751XA SG 11201809751X A SG11201809751X A SG 11201809751XA SG 11201809751X A SG11201809751X A SG 11201809751XA SG 11201809751X A SG11201809751X A SG 11201809751XA
Authority
SG
Singapore
Prior art keywords
suite
cure
road
international
san diego
Prior art date
Application number
SG11201809751XA
Other languages
English (en)
Inventor
Kevin Bunker
Peter Huang
Sunny Abraham
Joseph Pinchman
Chad Hopkins
Deborah Slee
Original Assignee
Zeno Royalties & Milestones Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeno Royalties & Milestones Llc filed Critical Zeno Royalties & Milestones Llc
Publication of SG11201809751XA publication Critical patent/SG11201809751XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
    • C07C13/28—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
    • C07C13/32—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings
    • C07C13/36—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with a bicyclo ring system containing five carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/38—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing five carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SG11201809751XA 2016-05-26 2017-05-24 Egfr inhibitor compounds SG11201809751XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662342141P 2016-05-26 2016-05-26
PCT/US2017/034163 WO2017205459A1 (en) 2016-05-26 2017-05-24 Egfr inhibitor compounds

Publications (1)

Publication Number Publication Date
SG11201809751XA true SG11201809751XA (en) 2018-12-28

Family

ID=60411884

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201809751XA SG11201809751XA (en) 2016-05-26 2017-05-24 Egfr inhibitor compounds
SG10202102920QA SG10202102920QA (en) 2016-05-26 2017-05-24 Egfr inhibitor compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202102920QA SG10202102920QA (en) 2016-05-26 2017-05-24 Egfr inhibitor compounds

Country Status (15)

Country Link
US (3) US10513509B2 (el)
EP (1) EP3464275B1 (el)
JP (1) JP7030066B2 (el)
KR (2) KR102444835B1 (el)
CN (2) CN109311858B (el)
AR (1) AR110038A1 (el)
AU (2) AU2017269335B2 (el)
CA (1) CA3023176A1 (el)
ES (1) ES2979136T3 (el)
IL (2) IL263081B (el)
MX (2) MX2018013413A (el)
RU (1) RU2751341C2 (el)
SG (2) SG11201809751XA (el)
TW (1) TWI752033B (el)
WO (1) WO2017205459A1 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR110038A1 (es) 2016-05-26 2019-02-20 Kalyra Pharmaceuticals Inc Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos
CN108864079B (zh) * 2017-05-15 2021-04-09 深圳福沃药业有限公司 一种三嗪化合物及其药学上可接受的盐
CA3074073A1 (en) 2017-09-11 2019-03-14 Recurium Ip Holdings, Llc Continuous flow processes for making bicyclic compounds
CN110041302B (zh) * 2019-03-01 2021-11-30 南方医科大学 2-氨基-4-取代吡啶衍生物及其合成方法和应用
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
EP3974423A4 (en) * 2019-05-22 2023-06-21 Shanghai Hansoh Biomedical Co., Ltd. INHIBITOR CONTAINING AN INDOLE DERIVATIVE, METHOD FOR PREPARING IT AND ITS USE
WO2020245208A1 (en) 2019-06-04 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20230026383A (ko) * 2020-06-23 2023-02-24 선전 포워드 파머수티컬즈 코 엘티디 화합물의 염 및 염을 포함하는 약학적 조성물
KR20240027583A (ko) * 2021-04-30 2024-03-04 수조우 푸허 바이오파마 컴퍼니 리미티드 폐암 치료를 위한 피리미디닐아미노벤젠
WO2024064091A1 (en) * 2022-09-19 2024-03-28 Advenchen Pharmaceuticals, LLC Novel pyrimidine compound as kinase inhibitors with biological activities on egfr mutants
WO2024094064A1 (en) * 2022-11-02 2024-05-10 Suzhou Puhe Biopharma Co., Ltd Pyrimidinylaminobenzenes for treating lung cancer with distant metastasis
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1051350A (en) 1910-02-02 1913-01-21 Thomas Nogier Apparatus for the sterilization of liquids.
DE4124942A1 (de) 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5612340A (en) 1993-10-01 1997-03-18 Ciba-Geigy Corporation Pyrimidineamine derivatives and processes for the preparation thereof
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
ES2271283T3 (es) * 2001-07-03 2007-04-16 Vertex Pharmaceuticals Incorporated Isoxazolil-pirimidinas como inhibidores de las proteinas quinasas src y lck.
US7396940B2 (en) 2003-10-23 2008-07-08 Hoffmann-La Roche Inc. Combinatorial library of 3-aryl-1H-indole-2-carboxylic acid
US20080153869A1 (en) 2004-06-14 2008-06-26 Bressi Jerome C Kinase Inhibitors
EP1786813A2 (en) 2004-09-03 2007-05-23 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
KR20070110324A (ko) 2005-03-04 2007-11-16 머크 앤드 캄파니 인코포레이티드 항당뇨 활성을 갖는 융합 방향족 화합물
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
AU2007261440A1 (en) 2006-06-22 2007-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2008024978A2 (en) 2006-08-24 2008-02-28 Serenex, Inc. Tetrahydroindolone and tetrahydroindazolone derivatives
AU2008248186B2 (en) 2007-05-07 2014-02-06 Merck Sharp & Dohme Corp. Method of treatment using fused aromatic compounds having anti-diabetic activity
JP2010031249A (ja) 2008-06-23 2010-02-12 Sumitomo Chemical Co Ltd 組成物及び該組成物を用いてなる発光素子
SG10201510696RA (en) 2008-06-27 2016-01-28 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
DE102008052943A1 (de) * 2008-10-23 2010-04-29 Merck Patent Gmbh Azaindolderivate
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
US8846673B2 (en) 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
NZ598808A (en) 2009-09-09 2014-07-25 Celgene Avilomics Res Inc Pi3 kinase inhibitors and uses thereof
KR101116234B1 (ko) 2009-10-29 2014-03-06 (주)퓨쳐켐 (3-플루오로-2-히드록시)프로필 작용기가 도입된 아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
TW201219383A (en) 2010-08-02 2012-05-16 Astrazeneca Ab Chemical compounds
ES2552462T3 (es) 2010-10-14 2015-11-30 Jw Pharmaceutical Corporation Nuevo compuesto de un mimético de giro inverso y un procedimiento de producción y uso del mismo
BR112013023681A2 (pt) 2011-03-16 2016-12-13 Hoffmann La Roche compostos de álcool propargílico 6,5-heterocíclico e uso dos mesmos
US20140303163A1 (en) 2011-03-24 2014-10-09 Ying Luo Use of kinase inhibitors in preventing and treating inflammatory disorder
RS60190B1 (sr) 2011-07-27 2020-06-30 Astrazeneca Ab 2-(2,4,5-supstituisani-anilino) pirimidinski derivati kao egfr modulatori korisni za lečenje raka
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
JP6399660B2 (ja) 2012-04-10 2018-10-03 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア 癌治療用組成物および方法
CN103508961B (zh) 2012-06-26 2015-07-22 中美冠科生物技术（太仓）有限公司 抗肿瘤药物
US9738610B2 (en) 2012-09-24 2017-08-22 Whitehead Institute For Biomedical Research Indazole derivatives and uses thereof
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
CA3182876A1 (en) 2012-11-21 2014-05-30 Janssen Biotech, Inc. Bispecific egfr/c-met antibodies
WO2014178606A1 (en) 2013-04-29 2014-11-06 Chong Kun Dang Pharmaceutical Corp. Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same
US20180057603A1 (en) 2013-08-09 2018-03-01 The Trustees Of The University Of Pennsylvania Combination of IFN-gamma with Anti-ERBB Antibody for the Treatment of Cancers
EP3039015B1 (en) 2013-08-30 2019-10-30 PTC Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
EP3044593A4 (en) 2013-09-09 2017-05-17 Triact Therapeutics, Inc. Cancer therapy
CA2925057A1 (en) 2013-10-01 2015-04-09 Simon T. BARRY Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
CN104761544B (zh) 2014-01-03 2019-03-15 北京轩义医药科技有限公司 Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
WO2015112705A2 (en) 2014-01-24 2015-07-30 Clovis Oncology, Inc. Therapeutic combinations for treating cancer
WO2015127234A1 (en) 2014-02-20 2015-08-27 Board Of Regents, The University Of Texas System Use of ibrutinib to treat egfr mutant cancer
CN104860941B (zh) * 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
CN104876914B (zh) 2014-02-28 2017-04-19 山东轩竹医药科技有限公司 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
TW201622744A (zh) 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
CN108558842B (zh) 2014-03-06 2021-06-04 山东轩竹医药科技有限公司 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
WO2015150826A1 (en) 2014-04-04 2015-10-08 Astrazeneca Ab Combination of egfr inhibitor and mek inhibitor for use in the treatment of nras mutated cancer
US10106526B2 (en) * 2014-04-04 2018-10-23 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2015175965A1 (en) 2014-05-15 2015-11-19 The Research Foundation For Suny Compositions targeting the interaction domain between p27kip1 and brk and methods of use thereof
WO2015188777A1 (en) 2014-06-12 2015-12-17 Shanghai Fochon Pharmaceutical Co Ltd Certain protein kinase inhibitors
MA40240B1 (fr) 2014-06-19 2019-03-29 Ariad Pharma Inc Composés hétéroaryle d'inhibition de la kinase
CN105254615B (zh) 2014-07-11 2017-02-22 杭州华东医药集团新药研究院有限公司 苯胺嘧啶衍生物及其在制备抗恶性肿瘤药物中的用途
CN107074948B (zh) 2014-07-11 2022-01-28 根马布股份公司 结合axl的抗体
CN105315285B (zh) 2014-07-25 2017-12-08 上海海雁医药科技有限公司 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
WO2016023822A1 (en) 2014-08-15 2016-02-18 Boehringer Ingelheim International Gmbh Afatinib pharmaceutical kit for cancer treatment
CN104140418B (zh) 2014-08-15 2016-08-24 常州润诺生物科技有限公司 2-(2，4，5-取代苯胺)嘧啶衍生物及其用途
CN106458969A (zh) 2014-08-25 2017-02-22 四川海思科制药有限公司 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途
WO2016032003A1 (ja) 2014-08-30 2016-03-03 国立大学法人金沢大学 肺癌患者用治療剤及び肺癌患者治療の有効性の予測検査方法
AU2015313811A1 (en) 2014-09-08 2017-04-06 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)
WO2016038609A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
US20170190788A1 (en) 2014-09-11 2017-07-06 Bulldog Pharmaceuticals, Inc. Uses of anti-her3 antibodies for treating cancer
US10669588B2 (en) 2014-09-26 2020-06-02 Hi-Stem Ggmbh Methods for sub-typing and treating cancer
CN105461695B (zh) 2014-09-29 2018-03-27 齐鲁制药有限公司 嘧啶或三嗪衍生物及其制备方法和用途
CN105237515B (zh) 2014-10-10 2018-06-05 益方生物科技（上海）有限公司 氘代嘧啶类化合物、其制备方法、药物组合物和用途
KR102589982B1 (ko) * 2014-10-11 2023-10-17 상하이 한서 바이오메디컬 컴퍼니 리미티드 Ｅｇｆｒ 억제제, 및 이의 제조 및 적용
BR112017007769B1 (pt) * 2014-10-13 2023-10-10 Yuhan Corporation Compostos derivados de aminopirimidina, composição farmacêutica que compreende os ditos compostos e uso terapêutico dos mesmos
US10308648B2 (en) 2014-10-16 2019-06-04 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN111170998B (zh) 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
JP6769962B2 (ja) 2014-12-03 2020-10-14 オークランド ユニサービシーズ リミティド 癌治療のためのキナーゼ阻害剤プロドラッグ
US10590111B2 (en) 2014-12-11 2020-03-17 Beta Pharma, Inc. Substituted 2-anilinopyrimidine derivatives as EGFR modulators
WO2016105582A1 (en) 2014-12-24 2016-06-30 Nunn Philip A Compositions for ileo-jejunal drug delivery
WO2016112272A1 (en) 2015-01-09 2016-07-14 Metastat, Inc. Method of use for inhibitors of epidermal growth factor receptor variant iii
WO2016112302A1 (en) 2015-01-09 2016-07-14 Metastat, Inc. Method of predicting sensitivity of tumor cell growth to combination therapy of fgfr inhibitor
SG11201705952SA (en) 2015-02-04 2017-09-28 Beyondbio Inc Heterocyclic compound and pharmaceutical composition comprising same
CN104961731A (zh) 2015-02-05 2015-10-07 苏州晶云药物科技有限公司 一种表皮生长因子受体抑制剂的磷酸盐、其晶型及制备方法
KR20170109589A (ko) 2015-02-05 2017-09-29 티르노보 리미티드 암 치료를 위한 irs/stat3 이중 조절제 및 항암제의 조합물
CN105985323A (zh) 2015-02-15 2016-10-05 宁波文达医药科技有限公司 新型表皮生长因子受体抑制剂及其应用
US20180087114A1 (en) 2015-03-05 2018-03-29 Trovagene, Inc. Early assessment of mechanism of action and efficacy of anti-cancer therapies using molecular markers in bodily fluid
CN106138061B (zh) 2015-04-03 2019-06-04 中国人民解放军第三军医大学第三附属医院 预防或减弱肺纤维化的复合物及其制剂和用途
CN106138020A (zh) 2015-04-03 2016-11-23 中国人民解放军第三军医大学第三附属医院 双胍类药物在制备预防或减弱肺纤维化的药物中的应用
WO2016164217A1 (en) 2015-04-09 2016-10-13 Clovis Oncology, Inc. Therapeutic combinations for treating cancer
CN104844580B (zh) 2015-04-17 2017-10-20 中国药科大学 嘧啶类化合物、其制备方法及医药用途
US20180147279A1 (en) 2015-04-23 2018-05-31 Medimmune Limited Combination therapy for non-small cell lung cancer positive for egfr mutation
CN104817541B (zh) 2015-05-11 2017-06-16 苏州东南药业股份有限公司 一种抗肿瘤药物的合成方法
US10881664B2 (en) 2015-05-15 2021-01-05 Novartis Ag Methods for treating EGFR mutant cancers
CN108135168B (zh) 2015-05-21 2021-07-20 凯莫森特里克斯股份有限公司 Ccr2调节剂
US20180117053A1 (en) 2015-05-27 2018-05-03 Metastat, Inc. The Method of Use for Inhibitors of Epidermal Growth Factor Receptor Variants II, III and VI
WO2016197012A1 (en) 2015-06-03 2016-12-08 Orient Pharma Inc. Methods and compositions for treating non-small cell lung cancer
US20160355503A1 (en) 2015-06-04 2016-12-08 Cleave Biosciences, Inc. NITROGEN HEXACYCLE COMPOUNDS AS INHIBITORS OF p97 COMPLEX
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CN104910049B (zh) 2015-06-16 2016-06-29 苏州明锐医药科技有限公司 Azd9291中间体及其制备方法
PT3319993T (pt) 2015-07-10 2020-04-22 Genmab As Conjugados de anticorpo-fármaco específicos de axl para tratamento de cancro
ES2964607T3 (es) 2015-07-17 2024-04-08 Pacylex Pharmaceuticals Inc Silenciamiento epigenético de NMT2
EP3325469A4 (en) 2015-07-20 2019-01-23 Dana Farber Cancer Institute, Inc. NOVEL PYRIMIDINES USEFUL AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS
TW201716439A (zh) 2015-07-20 2017-05-16 美國禮來大藥廠 Ｈｅｒ３抗體
EP3120851A1 (en) 2015-07-21 2017-01-25 Pangaea Biotech S.L. 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
US10561646B2 (en) 2015-07-24 2020-02-18 Shanghai Haiyan Pharmaceutical Technology Co. Ltd. EGFR inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof
CN105001208A (zh) 2015-08-06 2015-10-28 南京雷科星生物技术有限公司 一种表皮生长因子受体egfr抑制剂及其制备方法与用途
WO2017031036A1 (en) 2015-08-14 2017-02-23 Gray Alana Lea Isothiocyanatostilbenes as a novel method and product for treating cancer
CN105153122B (zh) 2015-08-27 2018-07-20 上海圣考医药科技有限公司 [(吲哚-3-基)嘧啶-2-基]氨基苯基丙-2-烯酰胺衍生物及盐、制备方法、应用
CN110483485A (zh) 2015-09-02 2019-11-22 益方生物科技（上海）有限公司 嘧啶类化合物、其制备方法和医药用途
CN105126125A (zh) 2015-09-12 2015-12-09 复旦大学 一种氧化锌-钆-药物复合纳米粒子及其制备方法和应用
CA2995430C (en) 2015-09-25 2023-07-11 Dizal (Jiangsu) Pharmaceutical Co., Limited Compounds and methods for inhibiting jak
CN106588943B (zh) 2015-10-19 2018-10-16 广东东阳光药业有限公司 一种egfr抑制剂的盐、晶型及其用途
US20170115275A1 (en) 2015-10-23 2017-04-27 Arizona Board Of Regents On Behalf Of Arizona State University Engineered substrates for high-throughput generation of 3d models of tumor dormancy, relapse and micrometastases for phenotype specific drug discovery and development
US10093668B2 (en) 2015-10-28 2018-10-09 Northwestern University Substituted aromatic N-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (Mnk1) and 2 (Mnk2)
JP2018531983A (ja) 2015-11-02 2018-11-01 イエール ユニバーシティ タンパク質分解誘導キメラ化合物ならびにその調製方法および使用方法
CN106674202A (zh) 2015-11-05 2017-05-17 惠州信立泰药业有限公司 化合物a的二甲磺酸盐及其晶型和含有该盐的药物组合物
CN106699736A (zh) 2015-11-17 2017-05-24 惠州信立泰药业有限公司 化合物A甲磺酸盐的晶型γ和含有该晶型的药物组合物
CN105461729B (zh) 2015-11-18 2017-12-05 乳源瑶族自治县大众药品贸易有限公司 一种egfr抑制剂的盐、晶型及其用途
CN105294717B (zh) 2015-11-18 2017-12-22 乳源瑶族自治县大众药品贸易有限公司 一种egfr抑制剂的盐、晶型及其用途
RU2603960C1 (ru) 2015-11-19 2016-12-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Дихлорацетат n1,n2-дизамещенного n4-[4-(1-метил-1н-индол-3-ил)-пиримидин-2-ил]-5-метоксибензол-1,2,4-триамина в качестве модулятора egfr для лечения рака
RU2606949C9 (ru) 2015-11-19 2018-03-14 ЗАО "Р-Фарм" Замещенные N-{ 3-[4-(1-метил-1Н-индол-3-ил)пиримидин-2-иламино]-4-метоксифенил} -амиды в качестве модуляторов EGFR, предназначенные для лечения рака
CN105348267A (zh) 2015-12-01 2016-02-24 中山奕安泰医药科技有限公司 合成azd9291中间体的方法
AU2016362390B2 (en) 2015-12-03 2021-11-11 Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. Thieno-pyrimidine derivatives and uses thereof
WO2017096100A1 (en) 2015-12-03 2017-06-08 Shanghai Aeon Biotech Co., Ltd. Heterocycle compounds and uses thereof
CA3007644A1 (en) 2015-12-11 2017-06-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade
TWI623316B (zh) 2015-12-22 2018-05-11 Taiho Pharmaceutical Co Ltd Antitumor effect enhancer derived from pyrrolopyrimidine compound
CN105601620A (zh) 2015-12-25 2016-05-25 北京康立生医药技术开发有限公司 一种甲磺酸迈瑞替尼的制备方法
AU2016380190B2 (en) 2015-12-27 2019-03-14 NeuForm Pharmaceuticals, Inc. Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
CN106928150B (zh) 2015-12-31 2020-07-31 恩瑞生物医药科技（上海）有限公司 丙烯酰胺苯胺衍生物及其药学上的应用
TWI726968B (zh) 2016-01-07 2021-05-11 開曼群島商Ｃｓ醫藥技術公司 Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
AU2017206077B2 (en) 2016-01-08 2021-11-18 The Regents Of The University Of California Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery
MX2018008433A (es) 2016-01-08 2019-03-28 Euclises Pharmaceuticals Inc Combinacion de un compuesto de cromeno y un segundo agente activo.
CN105646454B (zh) 2016-01-19 2018-05-08 浙江大学 含异羟肟酸片段的2-芳胺基嘧啶类衍生物及制备和应用
TWI745345B (zh) 2016-02-01 2021-11-11 瑞典商阿斯特捷利康公司 製備奧希替尼（osimertinib，azd9291）或其鹽及「azd9291苯胺」或其鹽的改良方法
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
MX2021009540A (es) 2016-02-04 2022-12-14 Auransa Inc Composiciones farmaceuticas y metodos para contrarrestar la cardiotoxicidad inducida por quimioterapia.
CN108601781B (zh) 2016-02-04 2019-11-22 广州必贝特医药技术有限公司 作为检测点激酶1(chk1)抑制剂的3,5-二取代吡唑及其制备及应用
CN105585557B (zh) 2016-02-25 2018-06-22 清华大学 用于靶向治疗癌症的egfr抑制剂及其制备方法与应用
CN105777716B (zh) 2016-02-25 2018-04-10 清华大学 一种用于靶向治疗癌症的egfr抑制剂及其制备方法与应用
AR110038A1 (es) 2016-05-26 2019-02-20 Kalyra Pharmaceuticals Inc Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos
CN105886648A (zh) 2016-06-06 2016-08-24 武汉海吉力生物科技有限公司 用于检测egfr基因t790m突变的试剂盒
CN106366072B (zh) 2016-08-19 2018-12-07 上海工程技术大学 一种azd9291的制备方法
CN106366022B (zh) 2016-08-19 2018-03-13 上海工程技术大学 一种用于制备azd9291的中间体及其制备方法和应用
CN106397407B (zh) 2016-08-31 2018-09-04 浙江科聚化工有限公司 抗肿瘤药物azd9291衍生物的制备方法
CN106432231B (zh) 2016-09-09 2018-06-12 无锡佰翱得生物科学有限公司 Azd9291的药用盐、及其晶型和制备方法
CN106565522A (zh) 2016-09-29 2017-04-19 福格森（武汉）生物科技股份有限公司 一种由氟代芳香化合物制备烷氧基芳香化合物的方法
CN106496196B (zh) 2016-10-20 2019-07-02 南京雷科星生物技术有限公司 一种喹唑啉、吡啶并嘧啶或则双并嘧啶衍生物表皮生长因子抑制剂及其制备方法与用途
CN106543060B (zh) 2016-10-31 2018-11-06 湖南欧亚药业有限公司 一种奥斯替尼甲磺酸盐的制备方法
CN106668866A (zh) 2017-02-13 2017-05-17 江苏省中医药研究院 一种抗非小细胞肺癌的药物组合物及其应用
CN106883216B (zh) 2017-04-06 2020-03-13 张家港威胜生物医药有限公司 一种奥希替尼的制备方法

Also Published As

Publication number Publication date
EP3464275C0 (en) 2024-05-08
AU2021240162A1 (en) 2021-10-28
SG10202102920QA (en) 2021-05-28
AR110038A1 (es) 2019-02-20
CN112624954A (zh) 2021-04-09
US20200181120A1 (en) 2020-06-11
KR20190007434A (ko) 2019-01-22
IL281537A (en) 2021-05-31
RU2018138584A3 (el) 2020-06-26
US20210395230A1 (en) 2021-12-23
NZ747854A (en) 2020-09-25
JP2019516766A (ja) 2019-06-20
CN109311858B (zh) 2021-12-03
RU2018138584A (ru) 2020-06-26
EP3464275B1 (en) 2024-05-08
ES2979136T3 (es) 2024-09-24
JP7030066B2 (ja) 2022-03-04
AU2017269335A1 (en) 2018-12-13
WO2017205459A1 (en) 2017-11-30
KR20220130249A (ko) 2022-09-26
KR102444835B1 (ko) 2022-09-19
RU2751341C2 (ru) 2021-07-13
AU2017269335B2 (en) 2021-07-01
EP3464275A4 (en) 2019-10-30
IL263081B (en) 2021-04-29
EP3464275A1 (en) 2019-04-10
CN109311858A (zh) 2019-02-05
US20170342055A1 (en) 2017-11-30
TW201800384A (zh) 2018-01-01
CA3023176A1 (en) 2017-11-30
US10513509B2 (en) 2019-12-24
MX2021007773A (es) 2021-08-05
MX2018013413A (es) 2019-06-06
IL263081A (en) 2018-12-31
US11098030B2 (en) 2021-08-24
WO2017205459A8 (en) 2018-12-13
US12049460B2 (en) 2024-07-30
BR112018074232A2 (pt) 2019-03-06
TWI752033B (zh) 2022-01-11

Similar Documents

Publication Publication Date Title
SG11201809751XA (en) Egfr inhibitor compounds
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201808990QA (en) Compositions for topical application of compounds
SG11201811549UA (en) Boronic acid derivatives and therapeutic uses thereof
SG11201805645QA (en) Lsd1 inhibitors
SG11201807708SA (en) Estrogen receptor modulators
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201907023UA (en) Method of reducing neutropenia
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201806583XA (en) Compositions containing tucaresol or its analogs
SG11201900904PA (en) Methods for cross coupling
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201807597UA (en) Methods of treating depression using orexin-2 receptor antagonists
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof